Unveiling the biological role of sphingosine-1-phosphate receptor modulators in inflammatory bowel diseases.

ABSTRACT: Inflammatory bowel disease (IBD) is chronic inflammation of the gastrointestinal tract that has a high epidemiological prevalence worldwide. The increasing disease burden worldwide, lack of response to current biologic therapeutics, and treatment-related immunogenicity have led to major concerns regarding the clinical management of IBD patients and treatment efficacy. Understanding disease pathogenesis and disease-related molecular mechanisms is the most important goal in developing new and effective therapeutics. Sphingosine-1-phosphate (S1P) receptor (S1PR) modulators form a class of oral small molecule drugs currently in clinical development for IBD have shown promising effects on disease improvement. S1P is a sphingosine-derived phospholipid that acts by binding to its receptor S1PR an

SUBMITTER: Tourkochristou E 

PROVIDER: S-EPMC9850947 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature